CASTLE ROCK, Colo., Aug. 13 /PRNewswire-FirstCall/ -- AspenBio Pharma, Inc. an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for animals and humans, has been invited to present at the Noble Financial Two Double-0-Seven Small Cap Conference and Micro Cap Symposium to be held at Charleston Place, Charleston, South Carolina, August 20 & 21, 2007. AspenBio Pharma's CEO, Richard Donnelly, is scheduled to present on Tuesday, August 21 at 9:30 a.m. Eastern Time. He will discuss the development status of the company's human appendicitis blood test as well as their animal pharma segment.
The Noble Financial Two Double-0-Seven Small Cap Conference and Micro Cap Symposium will feature companies across a broad range of industry sectors. Senior executives will make group presentations to analysts and portfolio managers on their business strategy and outlook, and will be available for breakout sessions and one-on-one meetings. For further information about the invitation-only conference, please visit: http://www.two-007.net.
About Noble Financial
Now in its 22nd year, Noble Financial Group, Member NASD, SIPC, is a full-service capital markets firm driven by what is often overlooked by others -- a mission intent on uncovering the value embedded in the orphaned, undiscovered or misunderstood company. Noble Financial maintains a focus on converting market inefficiencies into profit opportunities and an uncompromising conviction for delivering a quality product. Noble Financial supports emerging growth companies through strategic advice, investment banking, market-making, sales and trading, comprehensive equity research, and the development of institutional support. For more information about Noble Financial, please visit: http://www.noblefinancialgroup.com.
About AspenBio Pharma, Inc.
AspenBio Pharma is an emerging bio-pharmaceutical company dedicated to the discovery, development, manufacture, and marketing of novel proprietary products, including those that enhance the reproductive efficiency of animals and that have large worldwide market potential. The company was originally formed to produce purified proteins for diagnostic applications and has become a leading supplier of human hormones to many of the nation's largest medical diagnostic companies and research institutions. The company has successfully leveraged this foundational science and technology expertise to rapidly develop an enviable late-stage pipeline of several novel reproduction hormone analogs for wide-ranging therapeutic use initially in bovine and equine species. AspenBio Pharma continues to advance the development and testing of its two first-generation blood-based human diagnostic tests designed to rapidly help diagnose or rule out appendicitis in patients complaining of abdominal pain. For more information, please visit: http://www.aspenbiopharma.com.
For more information contact: AspenBio Pharma, Inc. Gregory Pusey, Chairman 303-722-4008 Investor Relations: Liolios Group, Inc. Scott Liolios or Ron Both 949-574-3860
AspenBio Pharma, Inc.CONTACT: Gregory Pusey, Chairman of AspenBio Pharma, Inc.,+1-303-722-4008; or Scott Liolios or Ron Both, both of Liolios Group, Inc.,for AspenBio Pharma, Inc., +1-949-574-3860
